The Food and Drug Administration informed the public that Capricor Therapeutics’ investigational stem-cell therapy for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial. This statement from the agency runs counter to Capricor’s earlier public characterization of the same trial as successful. The source material is a news report from STAT that quotes the FDA’s assessment but does not include the agency’s full evaluation or the specific data elements on which the FDA based its conclusion.
In December, Capricor reported that its drug, called deramiocel, had achieved both the primary and secondary endpoints of a large, randomized Phase 3 study. According to the company’s announcement at that time, those results represented a striking finding in a disease that is fatal in childhood and has been difficult to treat despite advances in genetic medicine. The STAT article cites the company’s December statements but does not reproduce the trial protocol, the endpoint definitions, or the numerical results Capricor reported.
Capricor highlighted that the observed data came primarily from teenagers and young men who had already lost the ability to walk. This subgroup of people with Duchenne typically has fewer therapeutic options, making any credible evidence of benefit in this population particularly notable. The STAT report notes the population composition but does not provide detailed demographic tables, baseline characteristics, or subgroup analyses from the trial dataset.
Per Capricor’s December communication, deramiocel appeared to preserve upper-arm function in the trial population and to delay or prevent the onset of heart failure that most patients with Duchenne eventually experience. These claimed effects were described as clinically meaningful by the company. The STAT excerpt does not reproduce the measurements, scales, or cardiac endpoints used to support those claims, nor does it report effect sizes, confidence intervals, or p values.
The STAT article excerpt available in the source is limited. It confirms the core conflict — FDA says the trial did not meet its objectives while Capricor had earlier indicated success — but it does not include many critical details that clinicians, regulators, and investors typically seek. Specifically, the source does not report:
Because these items were not reported in the source article, readers should consider the absence of those details when interpreting the reported disagreement between Capricor and the FDA.
The STAT report was written by Jason Mast, a general assignment reporter who covers genetic medicine and rare disease. The story is published on STAT’s website and appears to be behind the STAT+ subscriber paywall; the publicly available excerpt contains the FDA’s key conclusion and summarizes Capricor’s earlier claims but does not include the full reporting that may be available to subscribers. The publicly posted article also contains navigation and subscription prompts that indicate additional content is exclusive to STAT+.
From the source material alone, it is clear there is a direct contradiction between the FDA’s assessment and Capricor’s December announcement about deramiocel. However, the clinical and regulatory implications cannot be fully assessed from the excerpt. Important questions left unanswered in the source include the magnitude of any treatment effect Capricor reported, whether the FDA’s finding reflects insufficient efficacy versus other concerns, and how regulators will proceed. The STAT article does not provide further data or a Capricor response in the publicly available portion; those details were not reported in the source.
Clinicians, researchers, and other stakeholders seeking a complete picture should consult the FDA’s official correspondence or full review documents and Capricor’s full clinical study report or regulatory filings. Those primary source documents were not provided in the STAT excerpt and therefore are outside the factual basis of this rewritten summary.